ClinicalTrials.gg
RecruitingNCT07425990FET-LET-2x2Updated Sep 29, 2026

FET-LET-2x2: Clinical Pregnancy Rates After Frozen Embryo Transfer in Natural and Modified Natural Cycles

An interventional study of Letrozole (Aromatase Inhibitors) and Choriogonadotropin alpha (r-hCG) in Infertility Female and Frozen Embryo Transfer (FET), sponsored by University of Novi Sad. Recruiting at 1 site in Serbia. Open to female participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by University of Novi Sad · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Sep 29, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this clinical trial is to learn whether different natural approaches to preparing the uterus for frozen embryo transfer (FET) can improve pregnancy success in women undergoing in vitro fertilization (IVF) treatment.

The main questions it aims to answer are:

  1. Is a completely natural menstrual cycle more successful than a natural cycle in which ovulation is triggered with medication when preparing for frozen embryo transfer?
  2. Does taking a medication called letrozole at the beginning of the cycle improve pregnancy success compared to not taking it?

Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.

Participants will:

  • Be randomly assigned to one of four groups
  • Undergo monitoring with ultrasound and blood hormone tests during their menstrual cycle
  • In some groups, take letrozole tablets for a few days early in the cycle
  • In some groups, receive a hormone injection to help control the timing of ovulation
  • Undergo frozen embryo transfer at the appropriate time
  • Receive standard hormonal support after embryo transfer
  • Researchers will compare four different approaches to see which one results in the highest chance of achieving a clinical pregnancy, confirmed by ultrasound.
02

Conditions studied

  • Infertility Female
  • Frozen Embryo Transfer (FET)

Browse trials for

Keywords

  • Natural cycle FET
03

In context

Infertility, Female

553 studies on the registry are indexed under Infertility, Female; 133 are open to participants now.

This study's planned enrollment of 120 is above the median of 100 across 378 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

University of Novi Sad is the lead sponsor of 28 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 to 40 years
  • Regular menstrual cycles (26-35 days)
  • Scheduled for frozen embryo transfer (FET) in a natural menstrual cycle
  • Normal gynecological ultrasound findings without uterine abnormalities
  • Ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Use of preimplantation genetic testing (PGT) for the transferred embryo
  • Use of donor oocytes
  • Inadequate embryo survival after thawing, defined as loss of viability in more than 50% of blastomeres
  • Irregular menstrual cycles
  • Presence of uterine abnormalities detected by ultrasound
  • Inability or unwillingness to provide written
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    True Natural Cycle Without Letrozole

    Participants undergo frozen embryo transfer in a true natural menstrual cycle without the use of either an aromatase inhibitor or ovulation trigger medication. Ovulation is monitored by ultrasound and serum hormone levels. Luteal phase support (vaginal progesterone 200 mg twice daily or subcutaneous progesterone 25 mg once daily) is initiated on the day of ultrasound-confirmed ovulation and continued until 12 weeks of gestation if pregnancy occurs.

    Drug: Progesterone

  • Experimental
    True Natural Cycle With Letrozole

    Participants undergo frozen embryo transfer (FET) in a true natural menstrual cycle with administration of the aromatase inhibitor letrozole (2.5 mg twice daily) from cycle days 3-7. Ovulation is monitored by ultrasound and serum hormone levels. Luteal phase support (vaginal progesterone 200 mg twice daily or subcutaneous progesterone 25 mg once daily) is initiated on the day of ultrasound-confirmed ovulation and continued until 12 weeks of gestation if pregnancy occurs.

    Drug: Letrozole (Aromatase Inhibitors) · Drug: Progesterone

  • Experimental
    Modified Natural Cycle Without Letrozole

    Participants undergo frozen embryo transfer in a modified natural menstrual cycle without the use of an aromatase inhibitor. When the dominant follicle reaches ≥17 mm and endometrial thickness is ≥7 mm, and after exclusion of a spontaneous LH surge by serum measurement, ovulation is triggered with recombinant human chorionic gonadotropin (hCG) 250 mcg. Luteal phase support (vaginal progesterone 200 mg twice daily or subcutaneous progesterone 25 mg once daily) is initiated 2 days after ovulation trigger and continued until 12 weeks of gestation if pregnancy occurs.

    Drug: Choriogonadotropin alpha (r-hCG) · Drug: Progesterone

  • Experimental
    Modified Natural Cycle With Letrozole

    Participants undergo frozen embryo transfer (FET) in a modified natural menstrual cycle with administration of letrozole (2.5 mg twice daily) from cycle days 3-7. Ultrasound monitoring begins between cycle days 8-10. When the dominant follicle reaches ≥17 mm and endometrial thickness is ≥7 mm, and after exclusion of a spontaneous LH surge by serum LH measurement, ovulation is triggered with recombinant human chorionic gonadotropin (hCG) 250 mcg. Luteal phase support (vaginal progesterone 200 mg twice daily or subcutaneous progesterone 25 mg once daily) is initiated 2 days after ovulation trigger and continued until 12 weeks of gestation if pregnancy occurs.

    Drug: Letrozole (Aromatase Inhibitors) · Drug: Choriogonadotropin alpha (r-hCG) · Drug: Progesterone

Interventions

  • DrugLetrozoleStudies of LetrozoleLetrozole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Letrozole 2.5 mg administered orally twice daily from cycle days 3-7 during the early follicular phase.

  • DrugChoriogonadotropin alpha (r-hCG)

    Drug pages: OvidrelStudies of OvidrelOvidrel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Chorionic GonadotropinStudies of Chorionic GonadotropinChorionic Gonadotropin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Recombinant human chorionic gonadotropin (hCG) 250 mcg administered subcutaneously to trigger ovulation when follicular and endometrial criteria are met.

  • Luteal phase support with either vaginal progesterone 200 mg twice daily or subcutaneous progesterone 25 mg once daily, initiated after ovulation (or 2 days after hCG trigger) and continued until 12 weeks of gestation if pregnancy occurs.

06

What researchers measure

Primary outcomes

  1. Clinical Pregnancy Rate

    Number of pregnancies with an ultrasound-confirmed gestational sac per embryo transfer.

    Time frame: Approximately 4-6 weeks after embryo transfer.

Secondary outcomes

  1. Biochemical Pregnancy Rate

    Number of pregnancies with elevated serum beta-human chorionic gonadotropin (β-hCG) levels measured two weeks after embryo transfer, per embryo transfer.

    Time frame: Two weeks after embryo transfer.

  2. Implantation Rate

    Number of ultrasound-confirmed gestational sacs divided by the number of embryos transferred.

    Time frame: Approximately 4-6 weeks after embryo transfer.

  3. Miscarriage Rate

    Pregnancy loss before 23 completed weeks of gestation, expressed per embryo transfer.

    Time frame: Up to 23 weeks of gestation.

07

Study locations

1 of 1 sites recruiting
  • Specialized Gynecological Hospital "Ferona" Novi Sad
    Novi Sad, 21000, Serbia
    Recruiting
    • Stevan Milatović, Associate Professor · Contactoffice@ferona.rs · +38121 3000220
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 143 non-industry interventional studies with no phase under Infertility, Female, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 11 months is below that.

Counting every sponsor, half of 156 studies reached it within 23 months; a quarter within 9 and three quarters within 39.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Mar 2026, on Sep 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2026
First posted
Feb 23, 2026
StartActual
Mar 13, 2026was Feb 2026
Primary completionEst.
Feb 2027
CompletionEst.
Mar 2027
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 29, 2026
Sites
Specialized Gynecological Hospital "Ferona" Novi Sad is now Recruiting
Sep 29, 2026
Start date
Feb 2026→Mar 13, 2026 (actual)
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    Not yet recruiting→Recruiting
    Specialized Gynecological Hospital "Ferona" Novi Sad is now Recruiting
    Start date Feb 2026→Mar 13, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07425990
Lead sponsor
University of Novi Sad
Responsible party
Jelena Vuković (teaching assistant, University of Novi Sad) — Principal investigator
First posted
Feb 23, 2026
Start date
Mar 13, 2026
Primary completion
Feb 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Sep 29, 2026

Study contacts

Jelena Vukovic, MD
Contact
jel.zor@gmail.com
+381643070647

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Letrozole · Ovidrel · Chorionic Gonadotropin

Start the discussion